On this page

Betamethasone Dipropionate

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Betamethasone Dipropionate
Generic name
Betamethasone Dipropionate
Dosage form
Lotion
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Cosette Pharmaceuticals, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
3
Packages
3
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Betamethasone Dipropionate .5 mg/g 308714 View
Betamethasone Dipropionate .5 mg/mL 308714 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Lotion
Route of administration
Topical
Presentations
6

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
071467
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 10, 1987
Sponsor
COSETTE PHARMS NC
Products on application
1
Submissions recorded
11
Products approved under application 071467.
Product Trade name Form Strength Ingredient Status TE Flags
071467-001 BETAMETHASONE DIPROPIONATE LOTION BETAMETHASONE DIPROPIONATE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 071467.
Type No. Action Status Date Review
Supplement 10 Labeling Approved January 14, 2003 —
Supplement 9 Manufacturing (CMC) Approved August 30, 2001 —
Supplement 8 Manufacturing (CMC) Approved July 7, 2000 —
Supplement 7 Manufacturing (CMC) Approved January 12, 2000 —
Supplement 6 Manufacturing (CMC) Approved September 5, 1996 —
Supplement 5 Manufacturing (CMC) Approved September 5, 1996 —
Supplement 4 Manufacturing (CMC) Approved September 5, 1996 —
Supplement 3 Manufacturing (CMC) Approved June 30, 1993 —
Supplement 2 Manufacturing (CMC) Approved April 1, 1993 —
Supplement 1 Manufacturing (CMC) Approved July 13, 1989 —
Original application 1 Approved August 10, 1987 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20221115). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20221115 HUMAN PRESCRIPTION DRUG · 20220228

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Betamethasone Dipropionate Lotion USP, 0.05% is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Apply a few drops of Betamethasone Dipropionate Lotion to the affected skin areas and massage lightly until it disappears. Apply twice daily, in the morning and at night. If an infection develops, appropriate antimicrobial therapy should be instituted. Betamethasone Dipropionate products should not be used with occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Betamethasone Dipropionate Lotion USP, 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in these preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently when betamethasone dipropionate lotion 0.05% is used as recommended in the DOSAGE AND ADMINISTRATION section. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria. Adverse reactions reported to be possibly or probably related to treatment with betamethasone dipropionate lotion 0.05% during a pediatric study include: paresthesia (burning), erythema, erythematous rash, and dry skin. These adverse reactions each occurred in a different patient; 4% of the 25 patient population, respectively. An adverse reaction reported to be possibly or probably related to treatment in 2 different patients, 8%, of the 25 patients is puritis. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.

Description

openFDA Drug Labeling

DESCRIPTION Betamethasone Dipropionate Lotion USP, 0.05% contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has high corticosteroid activity and slight mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone. Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C 28 H 37 FO 7 , a molecular weight of 504.6, and the following structural formula: Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of Betamethasone Dipropionate Lotion USP, 0.05% contains 0.64 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone) in a lotion base of carbomer homopolymer type B, isopropyl alcohol, and purified water. Sodium hydroxide is used to adjust pH. Image 1

OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: Betamethasone Dipropionate Lotion, USP 0.05% is supplied as follows: 60 mL bottles (NDC 0713-0807-53) Shake well before using. Store at 25°C, excursions permitted between 15° and 30°C. Protect from light and freezing. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 Iss. 03/2021 8-0807CPLNC1 VC7520

Adverse event reports

Source: openFDA FAERS
10,032
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: BETAMETHASONE DIPROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0713-0807-53 0713-0807 Cosette Pharmaceuticals, Inc. 1 BOTTLE in 1 CARTON (0713-0807-53) / 60 mL in 1 BOTTLE September 5, 2016
0168-0057-60 0168-0057 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 1 BOTTLE in 1 CARTON (0168-0057-60) / 60 mL in 1 BOTTLE August 12, 1985
45802-021-46 45802-021 Padagis Israel Pharmaceuticals Ltd 56.2 g in 1 BOTTLE, PLASTIC (45802-021-46) June 30, 2006
0713-0807 0713-0807 Cosette Pharmaceuticals, Inc. — September 5, 2016
0168-0057 0168-0057 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC — August 12, 1985
45802-021 45802-021 Padagis Israel Pharmaceuticals Ltd — June 30, 2006

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.